Cello Health PLC Director/PDMR Dealings and Total Voting Rights (5783P)
May 29 2018 - 10:45AM
UK Regulatory
TIDMCLL
RNS Number : 5783P
Cello Health PLC
29 May 2018
29 May 2018
Cello Health plc
("Cello" or "the Company")
Director / PDMR Dealings and Total Voting Rights
The Company notifies that, on 25 May 2018, Richard Marsham and
Minh Huynh, both of whom are persons discharging managerial
responsibilities of the Company, exercised options over 46,000, and
15,321 ordinary shares of 10 pence each ("Shares") in the capital
of the Company respectively. The new Shares will rank pari-passu
with existing Shares and have been admitted to trading under the
Company's existing block listing. The exercise prices paid were as
follows:
Name Number of Exercise price Type of option
options exercised paid per share scheme
(p)
----------------- ------------------- ---------------- ----------------
Approved Share
Richard Marsham 17,428 42 Option Plan
----------------- ------------------- ---------------- ----------------
PSP Option
Richard Marsham 16,000 10 Scheme
----------------- ------------------- ---------------- ----------------
Unapproved
Richard Marsham 12,572 42 Option Plan
----------------- ------------------- ---------------- ----------------
Approved Option
Minh Huynh 15,321 50 Plan
----------------- ------------------- ---------------- ----------------
Following the above exercise of options, Richard Marsham and
Minh Huynh sold 46,000 and 15,321 Shares respectively, all at a
price of 122 pence per share.
Following the issue of the new Shares, Cello's issued share
capital will comprise 105,112,253 Ordinary Shares, of which 453,000
Ordinary Shares are held in treasury. The total number of current
voting rights in the Company is therefore 104,659,253 Ordinary
Shares.
The above figure of 104,659,253 may be used by shareholders as
the denominator for the calculation by which they will determine if
they are required to notify their interest in, or a change in their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
Enquiries:
Cello Health plc 020 7812 8460
Mark Scott, Chief Executive
Mark Bentley, Finance Director
Cenkos Securities plc 0207 397 8900
Mark Connelly
Harry Hargreaves
Template for notification and public disclosure of transactions
by persons discharging managerial responsibilities and persons
closely associated with them
1 Details of the person discharging managerial
responsibilities / person closely associated
---- --------------------------------------------------------------------------
a) Name Richard Marsham
---- -------------------------- ----------------------------------------------
2 Reason for the notification
---- --------------------------------------------------------------------------
a) Position/status PDMR and director of Cello
Signal
---- -------------------------- ----------------------------------------------
b) Initial notification Initial notification
/Amendment
---- -------------------------- ----------------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
---- --------------------------------------------------------------------------
a) Name Cello Health plc
---- -------------------------- ----------------------------------------------
b) LEI 2138004TZYGZLWQP7N64
---- -------------------------- ----------------------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
---- --------------------------------------------------------------------------
a) Description of Options over ordinary shares
the financial of 10 pence each
instrument, type
of instrument
----
Identification ISIN: GB00B0310763
code
---- -------------------------- ----------------------------------------------
b) Nature of the 1. Exercise of options over
transaction Ordinary Shares of 10 pence
each, pursuant to Approved
Share Option Plan
2. Exercise of options over
Ordinary Shares of 10 pence
each, pursuant to PSP Option
Scheme
3. Exercise of options over
Ordinary Shares of 10 pence
each, pursuant to Unapproved
Option Plan
4. Sale of Ordinary Shares
---- -------------------------- ----------------------------------------------
c) Price(s) and volume(s)
---- ------------------ ----------------
Price(s) Volume(s)
---- ------------------ ----------------
1. 42p per 1. 17,428
share
2. 10p per 2. 16,000
share
3. 42p per 3. 12,572
share
4. 122p per 4. 42,000
share
------------------ ----------------
d) Aggregated information
----
- Aggregated volume 46,000
- Price Weighted average exercise
price of 30.87p per share
e) Date of the transaction 25 May 2018
---- -------------------------- ----------------------------------------------
f) Place of the transaction 1,2,3 - Outside trading
venue
4. London Stock Exchange
---- -------------------------- ----------------------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- -------------------------------------------------------------------------------
a) Name Minh Huynh
--- ------------------------- ----------------------------------------------------
2 Reason for the notification
--- -------------------------------------------------------------------------------
a) Position/status PDMR and director of Cello
Signal
--- ------------------------- ----------------------------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------- ----------------------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- -------------------------------------------------------------------------------
a) Name Cello Health plc
--- ------------------------- ----------------------------------------------------
b) LEI 2138004TZYGZLWQP7N64
--- ------------------------- ----------------------------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- -------------------------------------------------------------------------------
a) Description of Options over ordinary shares
the financial of 10 pence each
instrument, type
of instrument
---
Identification ISIN: GB00B0310763
code
--- ------------------------- ----------------------------------------------------
b) Nature of the 1. Exercise of options over
transaction Ordinary Shares of 10 pence
each, pursuant to Approved
Share Option Plan
2. Sale of Ordinary Shares
--- ------------------------- ----------------------------------------------------
c) Price(s) and volume(s)
--- ------------------ ----------------------
Price(s) Volume(s)
--- ------------------ ----------------------
1. 50p per 1. 15,321
share
2. 122p per 2. 15,321
share
------------------ ----------------------
d) Aggregated information N/A - single transaction
---
- Aggregated volume
- Price
e) Date of the transaction 25 May 2018
--- ------------------------- ----------------------------------------------------
f) Place of the transaction 1. Outside trading venue
2. London Stock Exchange
--- ------------------------- ----------------------------------------------------
About Cello Health plc
We are a global healthcare-focused advisory Group comprised of a
set of leading clinical, commercial advisory and digital delivery
capabilities. We currently service 24 of the top 25 pharmaceutical
clients globally as well as a wide range of biotech, diagnostics,
devices and other key non-healthcare clients.
We enable clients to differentiate their propositions and drive
brand success in ever more complex global markets. We deliver our
services through nearly 1,000 highly skilled professionals
utilising latest thinking, technology and digital solutions.
Cello Health plc delivers its services from an office network in
the UK, USA, and Asia, with hub offices in New York, Philadelphia,
London, Edinburgh, Farnham and Cheltenham.
For further information, please visit:
https://cellohealthplc.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFKCDQQBKDQPB
(END) Dow Jones Newswires
May 29, 2018 10:45 ET (14:45 GMT)
Cello Health (LSE:CLL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cello Health (LSE:CLL)
Historical Stock Chart
From Apr 2023 to Apr 2024